Shivaani Kummar

Shivaani Kummar is a prominent clinical researcher and medical oncologist at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) in Bethesda, Maryland. She holds a senior academic position in the Center for Cancer Research, contributing significantly to early-phase clinical trials and translational oncology.

Her research interests include:

• Medical Oncology and Hematology
• Development of targeted therapies for solid tumors
• Phase I clinical trials and pharmacokinetics
• Immunotherapy and combination regimens
• Biomarker-driven cancer treatment

Dr. Kummar's recent publications (2023–2025) reflect a strong focus on novel agents such as nirogacestat, larotrectinib, and immune checkpoint inhibitors, with work spanning from preclinical models to first-in-human trials. Her studies frequently explore mechanisms of response and resistance, aiming to optimize therapeutic strategies for advanced cancers.

She has played a key role in numerous clinical trials evaluating new drugs, often in collaboration with multidisciplinary teams across institutions. Her work contributes to advancing precision oncology and improving outcomes for patients with refractory cancers.